IDEAYA's Darovasertib Approval Assumption Now Collides With What Revenue Actually Looks Like—Or Doesn't
Ideaya Biosciences Inc (IDYA) is scheduled to report first-quarter 2026 earnings on May 5, 2026, with analysts expecting a loss of $1.07 per share. The central question for investors is whether the clinical-stage oncology company can demonstrate progress in its synthetic lethality-focused pipeline while managing cash burn, particularly as Wall Street projects a significant widening of losses compared to the prior year. With the stock trading at $28.90 and analysts maintaining overwhelmingly bullish ratings despite near-term profitability challenges, this report will test whether IDYA's development milestones can sustain investor confidence.
Part 1: Earnings Preview
Ideaya Biosciences is a clinical-stage precision medicine oncology company focused on synthetic lethality approaches to cancer treatment, with a pipeline targeting genetically defined patient populations. The company's lead programs include IDE196 (PKC inhibitor) and darovasertib (PKC inhibitor), alongside partnerships with major pharmaceutical companies including GSK and Biogen.
For the quarter ending March 2026, analysts expect IDYA to report a loss of $1.07 per share on the consensus of 5 estimates, ranging from a loss of $0.94 to $1.21. The company most recently reported a loss of $0.94 per share for the December 2025 quarter, beating estimates by 8.74%. Year-over-year, the expected loss of $1.07 represents a 30.49% deterioration compared to the $0.82 loss reported in the same quarter last year, reflecting increased investment in clinical development.
Clinical Pipeline Advancement: Investors will focus on updates from IDYA's ongoing Phase 2 and Phase 3 trials, particularly data readouts for IDE196 in GNAQ/GNA11-mutant uveal melanoma and progress in the MAT2A inhibitor program. Any advancement toward regulatory milestones or partnership expansions could validate the company's synthetic lethality platform despite near-term losses.
Cash Runway and Burn Rate: With the company operating at a loss and no product revenue, the quarterly cash burn rate and remaining runway are critical metrics. Analysts will scrutinize operating expenses and whether IDYA's partnerships are generating sufficient milestone payments to extend its financial flexibility without dilutive capital raises.
Partnership Momentum: IDYA's collaborations with GSK, Biogen, and others represent both validation and potential revenue streams. Any announcements of expanded partnerships, milestone achievements, or new licensing deals would signal confidence in the platform and provide non-dilutive funding to support operations.
Leading analysts maintain a Strong Buy consensus with 15 of 19 analysts rating the stock a Strong Buy, reflecting confidence in the long-term pipeline value despite near-term losses. The average price target of $52.62 implies substantial upside from current levels, suggesting the Street views the current valuation as an attractive entry point ahead of potential clinical catalysts.
Part 2: Historical Earnings Performance
Ideaya Biosciences has demonstrated a mixed earnings track record over the past four quarters, with three misses and one significant beat. In Q1 2025 (March), the company reported a loss of $0.82 versus estimates of $0.75, missing by 9.33%. The Q2 2025 (June) quarter saw another miss with a loss of $0.88 against estimates of $0.85, a 3.53% shortfall. The Q3 2025 (September) quarter produced an unusual positive surprise with reported earnings of $1.33 versus an estimate of $0.00, though the "N/A" surprise percentage suggests this may reflect a one-time event or accounting adjustment rather than operational profitability. Most recently, Q4 2025 (December) delivered a modest beat with a loss of $0.94 versus estimates of $1.03, an 8.74% positive surprise.
The pattern reveals a company in heavy investment mode with losses generally in the $0.80-$0.95 range, excluding the anomalous Q3 result. The two most recent quarters show improving estimate accuracy, with IDYA coming in slightly better than expected after earlier misses. However, the year-over-year comparison is concerning: the $1.07 consensus for the upcoming quarter represents a 30% deterioration from the $0.82 loss in the same quarter last year, indicating accelerating cash burn as clinical programs advance. Investors should expect continued losses as the company prioritizes pipeline development over near-term profitability, with quarterly performance likely hinging on milestone payments and partnership activity rather than operational efficiency.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Mar 2025 | $-0.75 | $-0.82 | -9.33% | Miss |
| Jun 2025 | $-0.85 | $-0.88 | -3.53% | Miss |
| Sep 2025 | $0.00 | $1.33 | N/A | Beat |
| Dec 2025 | $-1.03 | $-0.94 | +8.74% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Ideaya Biosciences typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-02-17 | +$0.49 (+1.62%) | $1.81 (5.99%) | +$0.16 (+0.52%) | $0.70 (2.28%) |
| 2025-11-04 | -$0.88 (-2.81%) | $1.53 (4.88%) | -$0.82 (-2.69%) | $1.85 (6.07%) |
| 2025-08-05 | -$0.88 (-3.52%) | $2.42 (9.70%) | -$0.49 (-2.03%) | $1.11 (4.58%) |
| 2025-05-06 | -$2.72 (-13.29%) | $3.32 (16.22%) | +$0.08 (+0.45%) | $1.48 (8.34%) |
| 2025-02-13 | -$1.19 (-5.42%) | $1.20 (5.47%) | +$0.24 (+1.16%) | $0.85 (4.07%) |
| 2024-11-04 | +$1.40 (+4.90%) | $2.46 (8.60%) | -$0.42 (-1.40%) | $1.26 (4.20%) |
| 2024-08-06 | -$0.99 (-2.68%) | $1.82 (4.92%) | -$0.14 (-0.39%) | $1.17 (3.25%) |
| 2024-05-07 | -$0.34 (-0.79%) | $2.11 (4.90%) | -$1.34 (-3.13%) | $1.80 (4.21%) |
| Avg Abs Move | 4.38% | 7.58% | 1.47% | 4.62% |
Historical price behavior shows moderate volatility around earnings events, with an average absolute Day 0 move of 4.38% and Day +1 move of 1.47%. The Day 0 trading range averages 7.58%, indicating significant intraday volatility as investors position ahead of results, while the Day +1 range of 4.62% reflects continued uncertainty as the market digests the report.
The most dramatic reaction came in May 2025, when the stock plunged 13.29% on Day 0 with a 16.22% intraday range, suggesting a significant disappointment or guidance cut. More recently, the February 2026 report produced a modest 1.62% gain on Day 0 with a 5.99% range, indicating a more measured reaction. The November 2025 report saw a 2.81% decline on Day 0 followed by a 2.69% drop on Day +1, demonstrating how negative sentiment can persist into the following session.
Investors should prepare for a potential 4-8% swing in either direction based on historical patterns, with the magnitude likely depending on clinical updates and cash burn guidance rather than the EPS miss or beat itself. The relatively modest Day +1 follow-through (averaging 1.47%) suggests initial reactions tend to be overdone, creating potential entry or exit opportunities in the session following the report.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 05/15/26 (DTE 11) |
| Expected Move | $2.40 (8.29%) |
| Expected Range | $26.50 to $31.30 |
| Implied Volatility | 71.62% |
The options market is pricing an 8.29% expected move (±$2.40) for the May 15 expiration, which is significantly higher than the historical average Day 0 move of 4.38% but roughly in line with the average Day 0 trading range of 7.58%. This suggests options traders are anticipating above-average volatility for this particular report, possibly reflecting heightened uncertainty around clinical updates or partnership announcements that could drive outsized price action.
Part 3: What Analysts Are Saying
Analysts maintain overwhelmingly bullish sentiment on Ideaya Biosciences, with the current consensus rating of 4.63 out of 5.00 firmly in Strong Buy territory. The breakdown shows 15 Strong Buy ratings, 1 Moderate Buy, and 3 Hold ratings, with zero sell-side recommendations. This lopsided distribution reflects confidence in the company's synthetic lethality platform and clinical pipeline despite near-term profitability challenges.
The average price target of $52.62 implies 82% upside from the current price of $28.90, with estimates ranging from a low of $35.00 (21% upside) to a high of $78.00 (170% upside). This wide range suggests varying assumptions about the probability and timing of clinical success, but even the most conservative target implies meaningful appreciation potential.
Analyst sentiment has remained unchanged over the past month, with the same 15-1-3 Strong Buy/Buy/Hold distribution and identical average recommendation of 4.63. This stability suggests the analyst community is maintaining conviction in their bullish thesis despite recent stock weakness, viewing the current valuation as an attractive entry point ahead of potential clinical catalysts. The lack of downgrades following recent quarters indicates analysts view the widening losses as an expected and acceptable cost of advancing the pipeline rather than a fundamental concern.
Part 4: Technical Picture
The Barchart Technical Opinion has deteriorated significantly heading into earnings, currently showing a 56% Sell signal compared to 40% Sell one week ago and just 8% Sell one month ago. This rapid weakening suggests mounting technical pressure as the stock has failed to hold key support levels.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, with the stock struggling to attract buyers at current levels
- Medium-term (50% Sell): Moderate sell signal suggests the intermediate-term trend has also weakened, reflecting a loss of upward momentum over the past several weeks
- Long-term (50% Sell): Moderate sell signal indicates the longer-term trend has shifted to a cautionary posture, though not yet reaching extreme oversold territory
Trend Characteristics: The Soft Average trend environment suggests the stock is experiencing gradual deterioration rather than a sharp breakdown, but the consistency of sell signals across all timeframes indicates a lack of technical support heading into the earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $28.66 | 50-Day MA | $32.05 |
| 10-Day MA | $29.77 | 100-Day MA | $33.11 |
| 20-Day MA | $30.92 | 200-Day MA | $30.43 |
The stock is trading at $28.90, positioned above the 5-day moving average of $28.66 but below all other key moving averages: the 10-day ($29.77), 20-day ($30.92), 50-day ($32.05), and 100-day ($33.11). The stock is also below the 200-day moving average of $30.43, indicating it has lost long-term trend support. This configuration—above only the shortest-term average while below all intermediate and long-term averages—suggests a stock in a downtrend with only fleeting short-term bounces. The technical setup is cautionary heading into earnings, as the stock lacks the cushion of upward momentum and sits near recent lows. A positive surprise could trigger a sharp reversal given the oversold positioning, but a disappointment would likely accelerate the decline toward the next support level. Investors should be prepared for heightened volatility given the weak technical foundation and the options market's expectation of an 8% move.
